CPH •
Healthcare •
Biotechnology •
Quote as of 06/04/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeCPH
Market Capitalization57,080 mln
Float132 mln
Earnings Date05/04/2026
EPS
5.80
Stretched
P / E
45.90
High premium
1-Year Forecast
295
Modest upside
Relative Strength
80
/ 100
Strongly outperforming
Debt / Equity
0.06
Debt-free
ROE
20.91
Strong
Business Description
Founded in 1923 and based in Hørsholm, Denmark, ALK-Abelló is a medical company focused on helping people manage and treat allergies. Its core products include a range of immunotherapy treatments ? delivered as tablets, drops, or injections ? that target common allergies such as grass and tree pollen, house dust mites, ragweed, and peanuts, along with emergency medicines for severe allergic reactions like anaphylaxis. The company also offers diagnostic tools, a digital platform to help patients track and manage their condition, and is developing new biological treatments for food allergies. ALK-Abelló operates across Europe, North America, Asia, and other markets, working with partners such as Torii Pharmaceutical and Dr. Reddy's Laboratories to bring its products to patients worldwide.